How GLP-1 medications work for weight loss

If you have wondered why medications like Wegovy and Zepbound produce weight loss that diet and willpower rarely match, the answer is not a metabolism trick or a fat-burning stimulant. These drugs work upstream of all that, on the hormonal signals that tell your brain when you are hungry and when you have had enough. This guide explains, in plain language, how GLP-1 medications actually work, how semaglutide differs from tirzepatide, what the pivotal trials measured, and what those numbers mean for a real person. It is an educational overview, not medical advice or a promise of any particular result.

The short answer: how GLP-1 medications work for weight loss

GLP-1 medications work by mimicking glucagon-like peptide-1, a hormone your gut naturally releases after you eat. That hormone acts on appetite centers in the brain and on the digestive tract at once: it lowers hunger, raises the sense of fullness, and slows how quickly the stomach empties. The medication versions are engineered to last far longer than the natural hormone, a once-weekly injection instead of a signal that fades in minutes, so the appetite-quieting effect is present continuously rather than only right after a meal. The result is that most people eat less without the grinding effort that usually makes dieting fail.

Two different medicines dominate the weight-loss conversation, and they are not identical. Semaglutide acts on a single receptor, the GLP-1 receptor. Tirzepatide acts on two, adding the GIP receptor, which is why it is described as a dual agonist. We will come back to what that difference does.

What GLP-1 is, and why your body already uses it

GLP-1 is an incretin hormone. Cells in your intestine release it in response to food, and it does several useful things at once: it prompts the pancreas to release insulin when blood sugar is high, it tells the brain you are satisfied, and it slows digestion so nutrients arrive in the bloodstream more gradually. This is a normal part of how a healthy body manages a meal.

The catch is that natural GLP-1 breaks down within a couple of minutes. A GLP-1 receptor agonist is a lab-designed molecule that binds the same receptor but resists that rapid breakdown, so it keeps signaling for days. It is not adding a foreign mechanism to your body; it is amplifying and extending one you already have.

How the appetite effect actually happens

The weight-loss effect comes from several overlapping actions rather than one switch. Researchers who have mapped the biology describe it as a combination of central (brain) and peripheral (gut) effects working together.

• It acts directly on the brain’s appetite centers. GLP-1 signaling reaches hypothalamic regions that govern hunger, including the arcuate and paraventricular nuclei, activating appetite-suppressing pathways and dampening appetite-stimulating ones. Injecting GLP-1 into the brain reduces food intake even independent of what is happening in the stomach (mechanistic review, PMC).
• It slows gastric emptying. By slowing how fast the stomach passes food along, GLP-1 keeps you feeling full for longer after a meal. It also increases the volume the upper stomach can hold, a process called gastric accommodation, which changes how much fullness you feel as you eat (mechanistic review, PMC).
• It enhances the body’s own satiety signaling. Fullness signals travel from the stomach up the vagus nerve to the brainstem, and GLP-1 amplifies those signals so a smaller amount of food registers as “enough” (mechanistic review, PMC).

Put together, these actions produce weight loss mainly by reducing how much you eat, a negative energy balance driven by lower calorie intake, rather than by burning calories faster (mechanistic review, PMC). That is why so many people describe the experience as “food noise getting quieter”: the constant background pull toward eating simply eases.

Semaglutide vs tirzepatide: one receptor or two

Both medicines quiet appetite, but they engage different receptors, and that is the single most important distinction to understand.

Semaglutide is a pure GLP-1 receptor agonist. It targets the GLP-1 pathway described above and nothing else. It is the active molecule in Wegovy (approved for chronic weight management) and Ozempic (approved for type 2 diabetes).

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Alongside the GLP-1 receptor, it also activates the receptor for glucose-dependent insulinotropic polypeptide (GIP), a second incretin hormone. The two-receptor design is thought to act synergistically to enhance the appetite and metabolic effects (SURMOUNT-1, NEJM). Tirzepatide is the active molecule in Zepbound (approved for chronic weight management) and Mounjaro (approved for type 2 diabetes).

The practical upshot is that adding the GIP action appears to increase the average magnitude of weight loss, which is exactly what the head-to-head trial data suggests. For a deeper side-by-side comparison of the two, see semaglutide vs tirzepatide. For the wider set of compounds discussed as peptides for weight loss, and how far the evidence behind each one reaches, see our guide to peptides for weight loss.

What the pivotal trials actually showed

Averages from the large registration trials are the most honest way to set expectations, because they come from thousands of people followed for more than a year. Note that these are trial results under study conditions, paired with diet and activity counseling, individual results vary.

Semaglutide (STEP 1). In the STEP 1 trial of 1,961 adults with overweight or obesity and without diabetes, once-weekly semaglutide 2.4 mg produced a mean body-weight change of −14.9% at week 68, versus −2.4% for placebo. About 86% of people on semaglutide lost at least 5% of their body weight, roughly 69% lost at least 10%, and about half lost at least 15% (STEP 1, NEJM).

Tirzepatide (SURMOUNT-1). In the SURMOUNT-1 trial of 2,539 adults with obesity or overweight and without diabetes, mean weight reduction at week 72 was about 15% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% for placebo (SURMOUNT-1, NEJM).

Head-to-head (SURMOUNT-5). The two medicines were later compared directly. In SURMOUNT-5, among 751 adults with obesity and without diabetes, tirzepatide produced a mean weight change of −20.2% versus −13.7% for semaglutide over 72 weeks, a statistically significant difference favoring tirzepatide (about 22.8 kg versus 15.0 kg) (SURMOUNT-5, ACC journal scan).

A newer, higher-dose semaglutide option has since arrived. In March 2026 the FDA approved Wegovy HD (semaglutide 7.2 mg), the highest semaglutide dose approved for chronic weight management, which produced about 20.7% mean weight loss in its phase 3 STEP UP trial (FDA approval announcement).

Why “average” matters, and what it does not promise

These are averages, and averages hide real variation. Some people respond much more strongly to one medicine than the other, some tolerate one better, and factors like starting weight, adherence, dose reached, and lifestyle all move an individual result away from the headline number. A 13.7% average with semaglutide is a large, clinically meaningful outcome even though tirzepatide’s average was higher; conversely, no one is guaranteed the 20% figure just because it appeared in a trial. The right way to read these numbers is as evidence of what the class can do, not a prediction for any one person.

It also matters that the medication is designed to work alongside nutrition and activity, not to replace them. The trials paired the drug with lifestyle counseling, and preserving muscle while losing weight is worth planning for deliberately, see preserving muscle on a GLP-1.

One more piece of context follows directly from the mechanism: because these drugs work by continuously suppressing appetite, that appetite suppression fades once the medication is stopped. In the trials, the effect depended on ongoing treatment rather than resetting the body permanently, which is why clinicians generally frame obesity as a chronic condition managed over time rather than something cured in a single course. Understanding that up front changes how you plan, it is the difference between a short experiment and a long-term strategy. We cover the details separately in what happens when you stop a GLP-1.

Which GLP-1 medications are FDA-approved for weight loss?

Two branded medicines are FDA-approved for chronic weight management, and they are FDA-approved products you can describe as such:

• Wegovy (semaglutide), indicated, together with a reduced-calorie diet and increased physical activity, for chronic weight management in adults with obesity or overweight with a weight-related condition, and in adolescents 12 and older with obesity (Wegovy label, DailyMed).
• Zepbound (tirzepatide), indicated to reduce excess body weight and maintain the reduction in adults with obesity, or overweight with a weight-related condition, and separately for moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound label, DailyMed).

The same two molecules are sold under different brand names, Ozempic (semaglutide) and Mounjaro (tirzepatide), but those products are FDA-approved for type 2 diabetes glycemic control, not for weight loss (Ozempic label, DailyMed; Mounjaro label, DailyMed). Using them for weight loss is an off-label decision a prescriber is responsible for explaining.

It is worth being precise about one thing: compounded versions of semaglutide and tirzepatide have not been evaluated or approved by the FDA and should not be treated as equivalent to these branded products. If you are weighing how to access treatment, our guide to GLP-1 weight-loss treatment online in 2026 walks through what changed and what a legitimate route looks like.

What to expect physically: side effects and dosing follow the mechanism

The mechanism also explains the side effects. Because these drugs slow the stomach and act on the gut, the most common effects are gastrointestinal, nausea, diarrhea, constipation, and occasional vomiting. In STEP 1, gastrointestinal events were the most frequently reported category with semaglutide (STEP 1, NEJM), and GI events were likewise the predominant side effects with tirzepatide in SURMOUNT-1 (SURMOUNT-1, NEJM).

This is precisely why the dose is not started at the top. Providers begin low and increase gradually over weeks, a process called titration, to let the body adjust and to keep side effects tolerable. For how that schedule works, see GLP-1 dosing and titration explained.

Managing the common effects is largely about pacing and habits, and it is covered in detail in GLP-1 side effects and how to manage them. A few points are worth keeping in mind up front. These medicines require a prescription and ongoing clinical oversight, not a one-time purchase; the labels also warn against combining a GLP-1 with another GLP-1 or with any other product that contains the same molecule, which is a real risk when the same drug is sold under several brand names. Beyond the gut symptoms, the prescribing information for these products carries a boxed warning about a risk of thyroid C-cell tumors seen in rodents, and they are not for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (Wegovy label, DailyMed; Zepbound label, DailyMed). This is exactly the kind of judgment a provider makes before writing a prescription, and part of why the mechanism being powerful is also a reason for medical supervision rather than a reason to shortcut it.

The bottom line

GLP-1 medications work for weight loss by extending a natural gut hormone that quiets hunger in the brain, heightens fullness, and slows the stomach, so eating less stops being a constant fight. Semaglutide works through the GLP-1 receptor; tirzepatide adds the GIP receptor, and in head-to-head data that dual action produced greater average weight loss. The pivotal trials show large, meaningful average results, roughly 15% with semaglutide 2.4 mg and about 21% with tirzepatide 15 mg, while leaving real room for individual variation and no guarantees. The FDA-approved weight-management options are Wegovy and Zepbound, used with nutrition and activity and under a licensed provider’s care. To go deeper, compare semaglutide vs tirzepatide or read how GLP-1 dosing and titration is handled in practice.